Billions of dollars are at stake, so the fight over who owns CRISPR is back in court
Posted by btwatson on April 30, 2018 8:35 pm
Source: Billions of dollars are at stake, so the fight over who owns CRISPR is back in court
Credit for a game-changing breakthrough in biotechnology, a potential Nobel Prize, and oh yes, gobs of money have proved motive enough for the University of California, Berkeley, to keep up its all-but-lost dispute with the Broad Institute of MIT and Harvard over who owns the rights to the gene-editing tool CRISPR. The two parties squared off again today in a federal court in Washington, DC.
Background: The Berkeley team and its collaborators first filed a patent application in May 2012 to use CRISPR in any kind of cell. In December of that year, Broad researchers filed an application but paid an extra fee for an expedited route to patent CRISPR in eukaryotic cells—those in plants, animals, and people. The Broad was granted several patents.
Patent fight: Berkeley challenged that decision, asking the US Patent & Trademark Office to reconsider. In a ruling last year, the office’s patent trial and appeal board decided in favor of the Broad, saying the two teams’ discoveries didn’t overlap and that the Broad’s patents were, in fact, valid.
Appeal: The University of California appealed that decision, and today it tried to convince federal judges in DC that the patent board made legal errors when it issued its ruling. The judges didn’t seem swayed—but they won’t issue a written decision until later this year at the earliest.
CRISPR’s future: At stake is likely to be billions of dollars in licensing agreements. If the Broad ultimately prevails, companies currently licensing technology from the University of California—like CRISPR Therapeutics and Intellia Therapeutics—will instead need to seek approval from the Broad Institute for rights to use CRISPR. That could send their stock tumbling and potentially delay their plans to begin clinical trials using the gene-editing technology.
- Emily Caulfield
Published at Mon, 30 Apr 2018 19:27:01 +0000
Panning for gold in a dependent-sea of genes - Fred Hutch News ServiceMarch 20, 2023
CRISPR Gene Editing Reverses 'Permanent' Vision Loss in Mice–Offering Hope for Retinitis Pigmentosa Patients - Good News NetworkMarch 19, 2023
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus ... - MarketBeatMarch 19, 2023
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time - NasdaqMarch 18, 2023
CRISPR Gene-Editing Technique Reverses Vision Loss in Mice - Neuroscience NewsMarch 17, 2023
Vision restored in mice thanks to refined CRISPR system - New AtlasMarch 17, 2023
Blind Mice Regain Eyesight After Crispr Gene Editing - ForbesMarch 17, 2023
It's Official: No More Crispr Babies—for Now – Legacy Medi4 - Legacy Medi4March 17, 2023
It’s Official: No More Crispr Babies—for Now - WIREDMarch 17, 2023
Spotted around the web: Brain imaging replicability; CRISPR-edited ... - Spectrum - Autism Research NewsMarch 17, 2023
Transcription factor bHLH121 regulates root cortical aerenchyma ... - pnas.orgMarch 16, 2023
Theoretical guarantees for phylogeny inference from single-cell ... - pnas.orgMarch 16, 2023
'Epigenetic Engineering' Gene Therapy From Epic Bio Shows Early ... - ScripMarch 16, 2023
Seamless Launches with $12.5M for Programmable Recombinases ... - BioSpaceMarch 16, 2023
Plantae Bioscience deploys CRISPR to eliminate bitter taste in ... - AgFunderNewsMarch 16, 2023
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.